AAO 2016 Ophthalmic technology event - news, content powered by VPO and PR Newswire http://aao.vporoom.com/ At-Home Vision Monitoring App May Improve Patient Care http://aao.vporoom.com/2017-11-12-At-Home-Vision-Monitoring-App-May-Improve-Patient-Care People with age-related macular degeneration or diabetic eye disease can successfully self-screen on a smartphone Sun, 12 Nov 2017 13:39:00 -0500 http://aao.vporoom.com/2017-11-12-At-Home-Vision-Monitoring-App-May-Improve-Patient-Care ZEISS unveils digitalization and diagnostic advancements for eye care at AAO 2017 http://aao.vporoom.com/2017-11-11-ZEISS-unveils-digitalization-and-diagnostic-advancements-for-eye-care-at-AAO-2017 New digital technologies and diagnostics from ZEISS maximize clinical efficiency and performance helping doctors advance ophthalmic care Sat, 11 Nov 2017 19:49:00 -0500 http://aao.vporoom.com/2017-11-11-ZEISS-unveils-digitalization-and-diagnostic-advancements-for-eye-care-at-AAO-2017 ZEISS introduces VERACITY Surgical at AAO 2017 http://aao.vporoom.com/2017-11-11-ZEISS-introduces-VERACITY-Surgical-at-AAO-2017 ZEISS introduces cloud-based cataract surgery planning platform, VERACITY Surgical, and announces integration with leading EMRs Sat, 11 Nov 2017 19:35:00 -0500 http://aao.vporoom.com/2017-11-11-ZEISS-introduces-VERACITY-Surgical-at-AAO-2017 World's Largest Clinical Specialty Database Yields Critical Insights to Advance Ophthalmic Patient Care http://aao.vporoom.com/2017-11-11-Worlds-Largest-Clinical-Specialty-Database-Yields-Critical-Insights-to-Advance-Ophthalmic-Patient-Care American Academy of Ophthalmology's quality of care initiative drives several new studies Sat, 11 Nov 2017 13:30:00 -0500 http://aao.vporoom.com/2017-11-11-Worlds-Largest-Clinical-Specialty-Database-Yields-Critical-Insights-to-Advance-Ophthalmic-Patient-Care Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness http://aao.vporoom.com/2017-11-10-Novartis-brolucizumab-RTH258-demonstrates-superiority-versus-aflibercept-in-key-secondary-endpoint-measures-of-disease-activity-in-nAMD-a-leading-cause-of-blindness - Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept Fri, 10 Nov 2017 18:00:00 -0500 http://aao.vporoom.com/2017-11-10-Novartis-brolucizumab-RTH258-demonstrates-superiority-versus-aflibercept-in-key-secondary-endpoint-measures-of-disease-activity-in-nAMD-a-leading-cause-of-blindness